US stocks are on the move | Positive results achieved in a heart disease drug trial Cytokinetics (CYTK.US) soared more than 20% in early trading.

According to the Zhitong Finance APP on Tuesday, Cytokinetics (CYTK.US) soared more than 20% in early trading, hitting a new high for the year at $79.72. On the news front, the company had previously announced that its key Phase 3 ACACIA-HCM trial had achieved positive preliminary results, meeting two primary endpoints. The trial evaluated the effectiveness of aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy patients. This heart disease is characterized by thickening of the heart muscle leading to symptoms such as shortness of breath, fatigue, and chest pain, but without significant blockages in blood flow. The trial showed statistically significant improvements compared to placebo in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) and maximal exercise performance, driving the stock surge after the announcement.